|
[1] World Health Organization.Global surveillance and control of hepatitis C.Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium[J].J Viral Hepat, 1999, 6 (1) :35-47.
|
|
[2] CHEN YS, LI L, CUI FQ, et al.A sero-epidemiological study on hepatitis C in China[J].Chin J Epidemiol, 2011, 32 (9) :888-891. (in Chinese) 陈园生, 李黎, 崔富强, 等.中国丙型肝炎血清流行病学研究[J].中华流行病学杂志, 2011, 32 (9) :888-891.
|
|
[3]XIE Y, XU DZ, LU ZM, et al.The influence of HCV genotype on the IFN treatment of patients with chronic C[J].Chin J Hepatol, 2004, 12 (2) :72-75. (in Chinese) 谢尧, 徐道振, 陆志檬, 等.HCV基因型对慢性丙型肝炎干扰素疗效的影响[J].中华肝脏病杂志, 2004, 12 (2) :72-75.
|
|
[4]XU B, LYU P, ZHU M.Epidemiological aspects of the genotype of hepatitis C virus[J].Chin J Exp Clin Virol, 2000, 14 (2) :148-150. (in Chinese) 徐蓓, 吕屏, 朱玫.慢性丙型肝炎患者HCV基因型调查[J].中华实验和临床病毒学杂志, 2000, 14 (2) :148-150.
|
|
[5]YAN Y, LI Z, GUO XH, et al.A study on HCV-RNA quantitative detection and genotype in Peking[J].J Med Theory Pract, 2007, 20 (7) :756-757. (in Chinese) 严艳, 李卓, 郭向华, 等.北京地区慢性丙型肝炎患者血清HCV-RNA定量检测与基因分型的研究[J].医学理论与实践, 2007, 20 (7) :756-757.
|
|
[6] HADZIYANNIS SJ, SETTE H JR, MORGAN TR, et al.Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose[J].Ann Intern Med, 2004, 140 (5) :346-355.
|
|
[7]AFDHAL NH.The natural history of hepatitis C[J].Semin Liver Dis, 2004, 24 (Suppl 2) :3-8.
|
|
[8] GHANY MG, STRADER DB, THOMAS DL, et al.Diagnosis, management, and treatment of hepatitis C:an update[J].Hepatology, 2009, 49 (4) :1335-1374.
|
|
[9]SHERMAN M, SHAFRAN S, BURAK K, et al.Management of chronic hepatitis C:consensus guidelines[J].Can J Gastroenterol, 2007, 21 (Suppl C) :25C-34C.
|
|
[10]Chinese Society of Hepatology and Chinese Society of Infectious Diseases and Parasitology, Chinese Medical Association.Guidelines for prevention and treatment of hepatitis C[J].J Clin Hepatol, 2004, 20 (4) :197-203. (in Chinese) 中华医学会肝病学分会、传染病与寄生虫病学分会.丙型肝炎防治指南[J].临床肝胆病杂志, 2004, 20 (4) :197-203.
|
|
[11]SAKAGUCHI S, SAKAGUCHI N, ASANO M, et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25) .Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol, 1995, 155 (3) :1151-1164.
|
|
[12] HORI S, NOMURA T, SAKAGUCHI S.Control of regulatory T cell development by the transcription factor Foxp3[J].Science, 2003, 299 (5609) :1057-1061.
|
|
[13] CALIGIURI M.Human nature killer cell[J].J Blood, 2008, 112 (3) :461-469.
|
|
[14] POLI A, MICHEL T, THRESINE M, et al.CD56bright natural killer (NK) cells:An important NK cell subset[J].Immunology, 2009, 126 (4) :458-465.
|
|
[15]MORETTA L, FERLAZZO G, BOTTINO C, et al.Effector and regulatory events during natural killer-dendritic cell interactions[J].Immunol Rev, 2006, 214 (1) :219-228.
|
|
[16]DESSOUKI O, KAMIYA Y, NAGAHAMA H, et al.Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion:Reversion byanti-viral treatment[J].Biochem Biophys Res Commun, 2010, 393 (2) :331-337.
|
|
[17]AMADEI B, URBANI S, CAZALY A, et al.Activation of natural killer cells during acute infection with hepatitis C virus[J].Gastroenterology, 2010, 138 (4) :1536-1545.
|
|
[18]MORISHIMA C, PASCHAL DM, WANG CC, et al.Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing[J].Hepatology, 2006, 43 (3) :573-580.
|
|
[19]LIN AW, GONZALEZ SA, CUNNINGHAM-RUNDLES S, et al.CD56 (+dim) and CD56 (+bright) cell activation and apoptosis in hepatitis C virus infection[J].Clin Exp Immunol, 2004, 137 (2) :408-416.
|
|
[20] YOSHIZAWA K, ABE H, KUBO Y, et al.Expansion of CD4 (+) CD25 (+) FoxP3 (+) regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma[J].Hepatol Res, 2010, 40 (2) :179-187.
|
|
[21]BOLACCHI F, SINISTRO A, CIAPRINI C, et al.Increased hepatitis C virus (HCV) -specific CD4+CD25+regulatory T lymphocytes and reduced HCV-specific CD4+T cell response in HCVinfected patients with normal versus abnormal alanine aminotransferase levels[J].Clin Exp Immunol, 2006, 144 (2) :188-196.
|
|
[22]TERME M, CHAPUT N, COMBADIERE B, et al.Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+self-reactive T cells[J].J Immunol, 2008, 180 (7) :4679-4686.
|
|
[23]LEE S, WATSON MW, FLEXMAN JP, et al.Increased proportion of the CD56 (bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy[J].J Med Virol, 2010, 82 (4) :568-574.
|
|
[24]BURTON JR, KLARQUIST J, IM K, et al.Prospective analysis of effector and regulatory CD4+T cells in chronic HCV patients undergoing combination antiviral therapy[J].J Hepatol, 2008, 49 (3) :329-338.
|
|
[25]LEE S, HAMMOND T, WATSON MW, et al.Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes frompatients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?[J].Clin Exp Immunol, 2010, 161 (1) :118-126.
|
|
[26]SOLDEVILA B, ALONSO N, MARTíNEZ-ARCONADA MJ, et al.A prospective study of T-and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4 (+) CD25 (+) CD127 (low/-) FoxP3 (+) T cells in patients with chronic HCV infection during pegylated interferon-alpha 2a plus ribavirin treatment[J].J Viral Hepat, 2011, 18 (6) :384-392.
|
|
[27]FRANCESCHINI D, PAROLI M, FRANCAVILLA V, et al.PDL1 negatively regulates CD4+CD25+Foxp3+Tregs by limiting STAT-5 phosphorylation in patients chronicallyinfected with HCV[J].J Clin Invest, 2009, 119 (3) :551-564.
|
|
[28]AKIYAMA M, ICHIKAWA T, MIYAAKI H, et al.Relationship between regulatory T cells and the combination of pegylated interferon and ribavirin for the treatment of chronic hepatitis type C[J].Intervirology, 2010, 53 (3) :154-160.
|
|
[29]TSENG KC, HO YC, HSIEH YH, et al.Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C[J].J Gastroenterol, 2012, 47 (7) :823-833.
|
DownLoad: